<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536870</url>
  </required_header>
  <id_info>
    <org_study_id>APP1165440</org_study_id>
    <nct_id>NCT04536870</nct_id>
  </id_info>
  <brief_title>Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study</brief_title>
  <acronym>STAREE-HEART</acronym>
  <official_title>STAREE-HEART Sub-study Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period&#xD;
      compared with placebo on markers of cardiac ageing. This will include determining global&#xD;
      longitudinal strain with transthoracic echocardiography, atrial fibrillation with home&#xD;
      measures twice daily for two weeks and changes in biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STAREE-HEART is a sub-study nested in the Statins in Reducing Events in the Elderly (STAREE)&#xD;
      double-blind randomised placebo-controlled trial. STAREE is investigating whether statins can&#xD;
      prolong good health and maintain independence amongst older people and is enrolling men and&#xD;
      women 70 years of age and over who are free from cardiovascular disease, diabetes and&#xD;
      dementia. STAREE-HEART will recruit a subset of 1000 STAREE participants before they are&#xD;
      randomised to STAREE study drug. STAREE-HEART will involve an additional suite of cardiac&#xD;
      assessments in these participants and will provide detailed information about the clinical&#xD;
      effect of statins on incidence of atrial fibrillation and heart failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global longitudinal strain (GLS) measured via transthoracic echocardiography.</measure>
    <time_frame>3 years</time_frame>
    <description>Change in global longitudinal strain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Atrial fibrillation (AF) measured via single lead handheld ECG recordings.</measure>
    <time_frame>3 years</time_frame>
    <description>Development of new AF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wavelet analysis via 12-lead ECG with Energy Waveform displays.</measure>
    <time_frame>3 years</time_frame>
    <description>Increases detection of Heart Failure (HF).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Healthy Ageing</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>STAREE Statin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in STAREE trial randomised to statin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAREE Placebo group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in STAREE trial randomised to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Ultrasound of heart</description>
    <arm_group_label>STAREE Placebo group</arm_group_label>
    <arm_group_label>STAREE Statin group</arm_group_label>
    <other_name>Global longitudinal strain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG screening</intervention_name>
    <description>Single lead ECG screening twice daily for two weeks</description>
    <arm_group_label>STAREE Placebo group</arm_group_label>
    <arm_group_label>STAREE Statin group</arm_group_label>
    <other_name>Alivecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ECG Screening</intervention_name>
    <description>12-lead ECG screening</description>
    <arm_group_label>STAREE Placebo group</arm_group_label>
    <arm_group_label>STAREE Statin group</arm_group_label>
    <other_name>12-lead ECG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged â‰¥70 years living independently in the community who are&#xD;
             participants in the STAREE RCT and eligible for randomisation to study medication.&#xD;
&#xD;
          -  Willing and able to provide informed consent and accept the STAREE-HEART study&#xD;
             requirements, including attendance for an echocardiogram and undertaking home&#xD;
             monitoring via ECG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known atrial fibrillation or atrial flutter.&#xD;
&#xD;
          -  Participants who do not wish to be informed of an abnormality under any circumstances,&#xD;
             regardless of severity, will not be enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid Hopper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Hopper</last_name>
    <phone>+61 3 99030569</phone>
    <email>ingrid.hopper@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha Gorgievski</last_name>
    <phone>+61 399030633</phone>
    <email>natasha.gorgievski@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Monash University; School of Public Health and Preventative Medicine: STAREE trial</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Ingrid Hopper</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Statin</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>STAREE</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Atrial fibrillation screening</keyword>
  <keyword>Global longitudinal strain</keyword>
  <keyword>Single time point screening</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

